Study Reveals Gut Bacteria's Role in Stubborn Obesity and Type 2 Diabetes - Video

Scientists are increasingly uncovering how the trillions of microbes living in the gut influence far more than digestion. A new review published in npj Biofilms and Microbiomes highlights how chemical signals produced by gut bacteria may contribute to the development of obesity and type 2 diabetes through the microbiota-gut-brain axis—a communication network linking the gut, brain, immune system, and metabolism.

According to the review, beneficial gut bacteria produce compounds such as short-chain fatty acids (SCFAs) that help regulate appetite, insulin sensitivity, and energy balance by supporting healthy brain signaling. However, an unhealthy diet and gut microbial imbalance, known as dysbiosis, can reduce these protective compounds while increasing harmful bacterial products, including lipopolysaccharides, which promote inflammation throughout the body.

Researchers explain that these inflammatory signals can disrupt the hypothalamus, a brain region responsible for controlling hunger and metabolism. At the same time, inflammation in fat tissue and the liver contributes to insulin resistance, while impaired communication between the gut and brain weakens signals that normally promote fullness after meals.

The review also highlights how microbial imbalances may interfere with the release of key gut hormones such as GLP-1 and PYY, which help regulate appetite and blood sugar. Excessive stimulation of insulin secretion and long-term inflammation may eventually exhaust insulin-producing beta cells in the pancreas, increasing the risk of type 2 diabetes.

However, the authors caution that translating these findings into clinical practice remains challenging. Responses to microbiome-based therapies are likely to vary depending on genetics, diet, existing gut microbiota, metabolic health, and disease stage. They conclude that personalized approaches will likely be essential as researchers continue exploring microbiome-targeted therapies for obesity and type 2 diabetes.

REFERENCE: Ma K, Zhang Q, Hao R, Sun X, Jia J, and Li M. 2026. The microbiota-gut-brain axis: novel mechanisms and therapeutic frontiers in obesity and type 2 diabetes. npj Biofilms and Microbiomes. https://www.nature.com/articles/s41522-026-01039-y